Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 15/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 1.00 |
| ▸ | HPGD | P15428 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.66 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Suksdorfin SCHEMBL15532093 | 0.96 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL27823975 | 0.96 | KDM4E (0.92) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL29912933 | 0.90 | KDM4E (0.84) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL29650634 | 0.90 | KDM4E (0.84) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL31127004 | 0.89 | KDM4E (0.83) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL31237484 | 0.88 | KDM4E (0.78) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL31153360 | 0.87 | KDM4E (0.76) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Visnadine SCHEMBL309874 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Visnadine SCHEMBL30640212 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Visnadine SCHEMBL12710639 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772252-B2 | Coumarin compounds as melanogenesis modifiers and uses thereof | NEW YORK UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772252-B2 | Coumarin compounds as melanogenesis modifiers and uses thereof | NEW YORK UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8563754-B2 | Compounds, compositions and methods for preventing skin darkening | NEW YORK UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563754-B2 | Compounds, compositions and methods for preventing skin darkening | NEW YORK UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| WO-2011094016-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | NEW YORK UNIVERSITY (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | NEW YORK UNIVERSITY | 2011-08-04 | — | — | US | disclosed |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | NEW YORK UNIVERSITY | 2011-08-04 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | KDM4E 4209/4885ALDH1A1 3582/4885HPGD 4457/4885 |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | TYR, MC1R, MITF | KDM4E 79/4885ALDH1A1 246/4885HPGD 2055/4885 |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | TYR, MC1R, MITF | KDM4E 274/4885ALDH1A1 397/4885HPGD 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.